期刊文献+

我国醛固酮检测方法性能和不同类型室间质量评价结果分析 被引量:3

Analysis on the performance of aldosterone testing and the results of EQA in China
原文传递
导出
摘要 目的:通过室间质量评价计划(EQA)对我国醛固酮检测方法的性能进行评价,以改进和提高醛固酮的实验室检测水平。方法:开展全国醛固酮常规EQA和正确度验证EQA。以5个浓度水平的冻干血清作为常规EQA的质评物,将检测结果按照仪器进行分组计算靶值和各组内的变异系数(CV)。以参考方法定值的3个浓度水平的冰冻人血清作为正确度验证EQA的质评物,计算各仪器组同靶值的偏差。结果:常规EQA有272家实验室回报结果,化学发光法占91.6%。放免法和质谱法的组内CV最大,稳健CV分别为14.6%~33.4%和43.5%~53.9%。其他化学发光法的组内CV大多小于10%。正确度验证计划结果显示,质谱法最准确,测定三个质评物的偏差分别为-7.9%、8.9%和-0.7%。其次是索灵,同靶值的偏差分别为58.7%、7.9%和-2.1%。其他化学发光法测定结果偏差较大,且与样本浓度负相关,个别系统偏差可达479%。结论:我国醛固酮实验室检测结果缺乏准确性和可比性,试剂厂商和实验室应重视EQA结果,对醛固酮进行准确溯源,改进并提高醛固酮检测质量。 Objective To evaluate the performance of aldosterone testing in China through the External Quality Assessment(EQA)and improve the testing quality of aldosterone.Methods Two kinds of EQA program for aldosterone were carried out in China,one of which is Routine EQA and the other is Trueness verification scheme.Lyophilized sera with 5 concentration levels were used as quality control of Routine EQA.The results were grouped according to the instrument.Target values and the coefficient of variation(CV)were calculated in each group.Trueness verification scheme was verified by using frozen human sera of 3 concentration levels determined by the reference method,and the bias of each instrument group from the target value was calculated.Results 272 laboratories submitted the testing results,and 91.6%of laboratories used chemiluminescence method.The maximum CV was obtained by radioimmunoassay and liquid chromatography mass spectrometry,and the robust CVs were 14.6%-33.4%and 43.5%-53.9%,respectively.For chemiluminescence methods,the robust group CV was less than 10%.The results of the Trueness verification scheme showed that liquid chromatography mass spectrometry method was the most accurate method,with biases of-7.9%,8.9%and-0.7%for the three quality controls.Diasorin system had the more accurate results deviated from the target by 58.7%,7.9%and-2.1%,respectively.The results of other chemiluminescence methods were negatively correlated with the sample concentration,and one of them with a bias of 479%.Conclusions The accuracy and comparability of aldosterone among laboratories in China are not satisfactory.Reagent manufacturers and laboratories should pay more attention to EQA,with the aldosterone results traceable to SI unit,and improve the test quality of aldosterone.
作者 周伟燕 罗文波 刘庆香 张江涛 马嵘 胡翠华 赵海建 张传宝 Zhou Weiyan;Luo Wenbo;Liu Qingxiang;Zhang Jiangtao;Ma Rong;Hu Cuihua;Zhao Haijian;Zhang Chuanbao(National Center for Clinical Laboratories,Beijing Engineering Research Center of Laboratory Medicine,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Obstetrics and Gynecology,Peking Union Medical College Hospital,Beijing 100730,China)
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2020年第3期267-273,共7页 Chinese Journal of Laboratory Medicine
基金 国家自然科学基金资助项目(81201337,81472035) 国家重点研发计划“重大慢性非传染性疾病防控研究”重点专项(2016YFC1305600,2016YFC1305603) 北京生物医药产业跨越发展工程项目(G20工程,Z161100001816043) 北京市东城区优秀人才培养资助项目。
关键词 醛固酮 质量控制 参考标准 Aldosterone Quality control Reference standards
  • 相关文献

参考文献4

二级参考文献25

  • 1张炜,汤正义,吴景程,王卫庆,宁光.静脉盐水负荷试验在原发性醛固酮增多症诊断中的应用[J].上海交通大学学报(医学版),2007,27(6):703-705. 被引量:22
  • 2Mosso L, Carvajal C, Gonzdlez A, et al. Primary aldosteronism and hypertensive disease [ J ]. Hypertension, 2003,42 ( 2 ) : 161 -165. DOI : 10.1161/01. HYP. 0000079505. 25750. l 1.
  • 3Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro [ J ]. Hypertension, 2007, 50 ( 3 ) : 447-453 ; discussion 447-453. DOI: 10. l l61/HYPERTENSIONAHA. 106. 086116.
  • 4Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore [ J ]. J Clin Eudocrinol Metab, 2000,85 ( 8 ) : 2854-2859. DOI: 10. 1210/ jcem. 85.8. 6752.
  • 5Sang X, Jiang Y, Wang W, et al. Prevalence of and risk factors forprimary aldosteronism among patients with resistant hypertension in China[J]. J Hypertens, 2013,31 (7) : 1465-1471 ; discussion 1471- 1472. DOI: 10. 1097/HJH. 0b013e328360ddf6.
  • 6Di MA, Petramala L, Cotesta D, et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism [ J ]. J Renin Angiotensin Aldosterone Syst, 2010, 11 (3) : 165-172. DOI : 10.1177/1470320310366581.
  • 7Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients[ J]. Arch Intern Med, 1981, 141(12) :1589-1593.
  • 8Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline [J]. J Clin Endocrinol Metab, 2008, 93(9) :3266-3281. DOI: 10. 1210/jc. 2008-0104.
  • 9Ahmed AH, Cowley D, Wolley M, et al. Seated saline suppression testing for the diagnosis of primary aldosteronism : a preliminary study [J]. J Clin Endocrinol Metab, 2014, 99 ( 8 ) : 2745-2753. DOI: 10. 1210/jc. 2014-1153.
  • 10Rossi GP, Auchus R J, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism[ J]. Hypertension, 2014, 63 ( 1 ) : 151-160. DOI: 10.1161/HYPERTENSIONAHA. 113. 02097.

共引文献173

同被引文献23

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部